Matthew Orlando Sells 38,491 Shares of Kenvue (NYSE:KVUE) Stock

Kenvue Inc. (NYSE:KVUE) General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Kenvue Stock Performance

Kenvue stock opened at $17.22 on Thursday. The company’s 50-day moving average price is $17.52 and its 200-day moving average price is $17.30. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. The company has a market cap of $33.05 billion, a PE ratio of 20.25, a price-to-earnings-growth ratio of 1.33 and a beta of 0.55. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $24.35.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.24 EPS. On average, equities research analysts forecast that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th will be paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. The ex-dividend date of this dividend is Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is presently 97.65%.

Hedge Funds Weigh In On Kenvue

Hedge funds have recently bought and sold shares of the business. Elyxium Wealth LLC bought a new stake in shares of Kenvue during the fourth quarter worth $26,000. Physician Wealth Advisors Inc. grew its holdings in shares of Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the last quarter. Cornerstone Planning Group LLC increased its stake in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares during the period. NBT Bank N A NY increased its stake in Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after buying an additional 1,006 shares during the period. Finally, MV Capital Management Inc. bought a new stake in Kenvue during the 4th quarter valued at about $28,000. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

KVUE has been the topic of several analyst reports. Canaccord Genuity Group boosted their target price on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. Jefferies Financial Group lowered shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Barclays cut their price objective on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 8th. Finally, UBS Group dropped their price target on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.